Back to Article
Mutational Analysis of Driver and Non-driver Mutations of Philadelphia Chromosome-negative Myeloproliferative Neoplasms; Diagnosis and Recent Advances in Treatment
World Journal of Cancer and Oncology Research
| Vol 3, Issue 1
Table 5. Clinical trials involving therapeuticagents as monotherapy or in combination with ruxolitinib (Adapted from: [81]).
| Agent | MPN-subtype | Mechanism of action | Phase | Clinical trial |
| LCL-161 | Primary, post-PV or post-ET and MF | IAPi | II | NCT02098161 |
| Navitoclax | MF receiving ruxolitinib | BCL-xLi | II | NCT03222609 |
| PU-H71 | MF receiving ruxolitinib | HSP-90i | II | NCT03935555 |
| Panobinostat | MF receiving ruxolitinib | HDACi | Ib | NCT01433445 |
| Idasanutlin | Hydroxyurea intolerant PV, | |||
| ET and MF without prior | ||||
| JAK2i | MDM2 inhibitor | I and II | NCT03287245 and NCT02407080 | |
| KRT-232 | Phlebotomy-dependent PV, and MF with JAK2i failure | MDM2 inhibitor | II | NCT03669965 and NCT03662126 |
| PRM-151 | MF | Pentraxin-2 inhibitor | II | NCT01981850 |
| Alisertib | MF | Aurora Kinase A inhibitor | II | NCT02530619 |
| Sotatercept | PMF and MPN-associated anemia | TGFβi | II | NCT01712308 |
| Luspatercept | PMF and MPN-associated anemia | TGFβi | II | NCT03194542 |
| AVID200 | MF | TGF-βi | I/Ib | NCT03895112 |
| Imetelstat | MF with JAK2i | Telomerase inhibitor | II | NCT02426086 |
| CPI-0610 | MF | BET inhibitor | II | NCT02158858 |